Tomas G. Neilan

Tomas G. Neilan

Auto-generated profile, based on publicly available information

Tomas G. Neilan

Massachusetts General Hospital, Harvard Medical School

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in JACC
Verified
Journal Article
Closed access
SMSyed S. Mahmood
Syed S. Mahmood
MFMichael G. Fradley
Michael G. Fradley
JCJustine V. Cohen
Justine V. Cohen
ANAnju Nohria
Anju Nohria
KRKerry L. Reynolds
Kerry L. Reynolds
TNTomas G. Neilan
Tomas G. Neilan

2 October 2020 in Circulation
Verified
Journal Article
Closed access
PDF file
Zsofia DrobniZsofia Drobni
Zsofia Drobni
RARaza M. Alvi
Raza M. Alvi
JTJana Taron
Jana Taron
AZAmna Zafar
Amna Zafar
SMSean P. Murphy
Sean P. Murphy
TNTomas G. Neilan
Tomas G. Neilan
Background: Immune checkpoint inhibitors (ICIs) treat an expanding range of cancers. Consistent basic data suggest that these same checkpoints are critical negative regulators of atherosclerosis. Therefore, our objectives were to test whether ICIs were associated with accelerated atherosclerosis and a higher risk of atherosclerosis-related cardiovascular events. Methods: The study was situated in a single academic medical center. The primary analysis evaluated whether exposure to an ICI was associated with atherosclerotic cardiovascular events in 2842 patients and 2842 controls matched by age, a history of cardiovascular events, and cancer type. In a second design, a case-crossover analysis was performed with an at-risk period defined as the 2-year period after and the control period as the 2-year period before treatment. The primary outcome was a composite of atherosclerotic cardiovascular events (myocardial infarction, coronary revascularization, and ischemic stroke). Secondary outcomes included the individual components of the primary outcome. In addition, in an imaging substudy (n=40), the rate of atherosclerotic plaque progression was compared from before to after the ICI was started. All study measures and outcomes were blindly adjudicated. Results: In the matched cohort study, there was a 3-fold higher risk for cardiovascular events after starting an ICI (hazard ratio, 3.3 [95% CI, 2.0–5.5]; P <0.001). There was a similar increase in each of the individual components of the primary outcome. In the case-crossover, there was also an increase in cardiovascular events from 1.37 to 6.55 per 100 person-years at 2 years (adjusted hazard ratio, 4.8 [95% CI, 3.5–6.5]; P 3-fold higher with ICIs (from 2.1%/y before 6.7%/y after). This association between ICI use and increased atherosclerotic plaque progression was attenuated with concomitant use of statins or corticosteroids. Conclusions: Cardiovascular events were higher after initiation of ICIs, potentially mediated by accelerated progression of atherosclerosis. Optimization of cardiovascular risk factors and increased awareness of cardiovascular risk before, during, and after treatment should be considered among patients on an ICI.

1 December 2019 in JACC
Verified
Journal Article
Closed access
RARaza M. Alvi
Raza M. Alvi
MFMatthew J. Frigault
Matthew J. Frigault
MFMichael G. Fradley
Michael G. Fradley
MJMichael D. Jain
Michael D. Jain
SMSyed S. Mahmood
Syed S. Mahmood
TNTomas G. Neilan
Tomas G. Neilan

7 May 2020 in European Heart Journal
Verified
Journal Article
Open access
PDF file
LZLili Zhang
Lili Zhang
MAMagid Awadalla
Magid Awadalla
SMSyed S Mahmood
Syed S Mahmood
ANAnju Nohria
Anju Nohria
MHMalek Hassan
Malek Hassan
TNTomas G Neilan
Tomas G Neilan
Aims: Myocarditis is a potentially fatal complication of immune checkpoint inhibitors (ICI). Sparse data exist on the use of cardiovascular magnetic resonance (CMR) in ICI-associated myocarditis. In this study, the CMR characteristics and the association between CMR features and cardiovascular events among patients with ICI-associated myocarditis are presented. Methods and results: From an international registry of patients with ICI-associated myocarditis, clinical, CMR, and histopathological findings were collected. Major adverse cardiovascular events (MACE) were a composite of cardiovascular death, cardiogenic shock, cardiac arrest, and complete heart block. In 103 patients diagnosed with ICI-associated myocarditis who had a CMR, the mean left ventricular ejection fraction (LVEF) was 50%, and 61% of patients had an LVEF ≥50%. Late gadolinium enhancement (LGE) was present in 48% overall, 55% of the reduced EF, and 43% of the preserved EF cohort. Elevated T2-weighted short tau inversion recovery (STIR) was present in 28% overall, 30% of the reduced EF, and 26% of the preserved EF cohort. The presence of LGE increased from 21.6%, when CMR was performed within 4 days of admission to 72.0% when CMR was performed on Day 4 of admission or later. Fifty-six patients had cardiac pathology. Late gadolinium enhancement was present in 35% of patients with pathological fibrosis and elevated T2-weighted STIR signal was present in 26% with a lymphocytic infiltration. Forty-one patients (40%) had MACE over a follow-up time of 5 months. The presence of LGE, LGE pattern, or elevated T2-weighted STIR were not associated with MACE. Conclusion: These data suggest caution in reliance on LGE or a qualitative T2-STIR-only approach for the exclusion of ICI-associated myocarditis.

1 February 2020 in JACC
Verified
Journal Article
Closed access
MAMagid Awadalla
Magid Awadalla
SMSyed S. Mahmood
Syed S. Mahmood
JGJohn D. Groarke
John D. Groarke
MHMalek Z.O. Hassan
Malek Z.O. Hassan
ANAnju Nohria
Anju Nohria
TNTomas G. Neilan
Tomas G. Neilan

16 June 2020 in Circulation
Verified
Journal Article
Closed access
PDF file
LZLili Zhang
Lili Zhang
DZDaniel A. Zlotoff
Daniel A. Zlotoff
MAMagid Awadalla
Magid Awadalla
SMSyed S. Mahmood
Syed S. Mahmood
ANAnju Nohria
Anju Nohria
TNTomas G. Neilan
Tomas G. Neilan